PortfoliosLab logoPortfoliosLab logo

Documentation

Upgrade your plan
TXG vs. BBP
Performance
Return for Risk
Drawdowns
Volatility
Dividends

TXG vs. BBP

Last updated Jun 4, 2026

TXG (10x Genomics, Inc.) is a stock, while BBP (Virtus LifeSci Biotech Products ETF) is Health & Biotech Equities fund tracking the LifeSci Biotechnology Products Index. Over the past 5 years, TXG returned -29.15%/yr vs 10.37%/yr for BBP. At a 0.48 correlation, their price movements are largely independent.

Performance

TXG vs. BBP - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in 10x Genomics, Inc. (TXG) and Virtus LifeSci Biotech Products ETF (BBP). The values are adjusted to include any dividend payments, if applicable.

Loading charts...

Returns By Period

In the year-to-date period, TXG achieves a 97.18% return, which is significantly higher than BBP's 5.80% return.

TXG

1D
4.72%
1M
48.55%
YTD
97.18%
6M
79.97%
1Y
253.02%
3Y*
-16.17%
5Y*
-29.15%
10Y*
—

BBP

1D
1.18%
1M
-3.14%
YTD
5.80%
6M
7.91%
1Y
45.02%
3Y*
16.70%
5Y*
10.37%
10Y*
11.61%
*Multi-year figures are annualized to reflect compound growth (CAGR)

TXG vs. BBP - Yearly Performance Comparison

2026 (YTD)2025202420232022202120202019
TXG
10x Genomics, Inc.		97.18%13.58%-74.34%53.57%-75.54%5.20%85.70%44.55%
BBP
Virtus LifeSci Biotech Products ETF		5.80%33.15%3.32%17.88%0.85%-8.17%22.24%14.29%

Correlation

The correlation between TXG and BBP is 0.37, which is low. Their price movements are largely independent, making them effective diversification partners.

Correlation
Correlation (1Y)
Calculated over the trailing 1-year period

0.37

Correlation (3Y)
Calculated over the trailing 3-year period

0.45

Correlation (5Y)
Calculated over the trailing 5-year period

0.51

Correlation (All Time)
Calculated using the full available price history since Sep 13, 2019

0.48

The correlation between TXG and BBP shifts across timeframes, from 0.37 (1 year) to 0.51 (5 years), reflecting how their relationship changes across market environments.

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.

10x Genomics, Inc.

Virtus LifeSci Biotech Products ETF

Often compared with TXG:
TXG vs. XDWT.DETXG vs. SBRATXG vs. METATXG vs. DHRTXG vs. SPYTXG vs. AAPLTXG vs. CRSP
Often compared with BBP:
BBP vs. BBCBBP vs. SBIOBBP vs. BTECBBP vs. FBTBBP vs. IBBQBBP vs. IHEBBP vs. WDNA

Return for Risk

TXG vs. BBP — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.
TXG
TXG Risk / Return Rank: 9595
Overall Rank
TXG Sharpe Ratio Rank: 9797
Sharpe Ratio Rank
TXG Sortino Ratio Rank: 9494
Sortino Ratio Rank
TXG Omega Ratio Rank: 9090
Omega Ratio Rank
TXG Calmar Ratio Rank: 9797
Calmar Ratio Rank
TXG Martin Ratio Rank: 9595
Martin Ratio Rank
BBP
BBP Risk / Return Rank: 6565
Overall Rank
BBP Sharpe Ratio Rank: 5656
Sharpe Ratio Rank
BBP Sortino Ratio Rank: 5656
Sortino Ratio Rank
BBP Omega Ratio Rank: 5050
Omega Ratio Rank
BBP Calmar Ratio Rank: 8686
Calmar Ratio Rank
BBP Martin Ratio Rank: 7979
Martin Ratio Rank
The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

TXG vs. BBP - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for 10x Genomics, Inc. (TXG) and Virtus LifeSci Biotech Products ETF (BBP). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

TXGBBPDifference

Sharpe ratio

Return per unit of total volatility

3.81

1.91

+1.90

Sortino ratio

Return per unit of downside risk

3.91

2.73

+1.17

Omega ratio

Gain probability vs. loss probability

1.45

1.32

+0.13

Calmar ratio

Return relative to maximum drawdown

9.15

4.87

+4.28

Martin ratio

Return relative to average drawdown

21.17

15.32

+5.85

Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month.

TXG vs. BBP - Sharpe Ratio Comparison

The current TXG Sharpe Ratio is 3.81, which is higher than the BBP Sharpe Ratio of 1.91. The chart below compares the historical Sharpe Ratios of TXG and BBP, calculated using daily returns over the previous 12 months. A higher Sharpe Ratio indicates better risk-adjusted performance relative to the risk-free rate.

Loading charts...

Sharpe Ratios by Period

TXGBBPDifference

Sharpe Ratio (1Y)

Calculated over the trailing 1-year period

3.81

1.91

+1.90

Sharpe Ratio (5Y)

Calculated over the trailing 5-year period

-0.43

0.40

-0.82

Sharpe Ratio (10Y)

Calculated over the trailing 10-year period

—

0.42

—

Sharpe Ratio (All Time)

Calculated using the full available price history

-0.11

0.39

-0.50

Drawdowns

TXG vs. BBP - Drawdown Comparison

The maximum TXG drawdown since its inception was -96.47%, which is greater than BBP's maximum drawdown of -44.32%. Use the drawdown chart below to compare losses from any high point for TXG and BBP.

Loading charts...

Drawdown Indicators

TXGBBPDifference

Max Drawdown

Largest peak-to-trough decline

-96.47%

-44.32%

-52.15%

Max Drawdown (1Y)

Largest decline over 1 year

-28.03%

-9.28%

-18.75%

Max Drawdown (3Y)

Largest decline over 3 years

-88.66%

-26.09%

-62.57%

Max Drawdown (5Y)

Largest decline over 5 years

-96.45%

-38.28%

-58.17%

Max Drawdown (10Y)

Largest decline over 10 years

—

-44.32%

—

Current Drawdown

Current decline from peak

-84.11%

-6.47%

-77.64%

Average Drawdown

Average peak-to-trough decline

-59.62%

-12.02%

-47.60%

Ulcer Index

Depth and duration of drawdowns from previous peaks

12.08%

2.95%

+9.13%

Volatility

TXG vs. BBP - Volatility Comparison

10x Genomics, Inc. (TXG) has a higher volatility of 16.46% compared to Virtus LifeSci Biotech Products ETF (BBP) at 7.61%. This indicates that TXG's price experiences larger fluctuations and is considered to be riskier than BBP based on this measure. The chart below showcases a comparison of their rolling one-month volatility.

Loading charts...

Volatility by Period

TXGBBPDifference

Volatility (1M)

Calculated over the trailing 1-month period

16.46%

7.61%

+8.85%

Volatility (6M)

Calculated over the trailing 6-month period

45.64%

18.43%

+27.21%

Volatility (1Y)

Calculated over the trailing 1-year period

67.46%

23.76%

+43.70%

Volatility (5Y)

Calculated over the trailing 5-year period, annualized

68.25%

26.35%

+41.90%

Volatility (10Y)

Calculated over the trailing 10-year period, annualized

66.73%

27.40%

+39.33%

Dividends

TXG vs. BBP - Dividend Comparison

Neither TXG nor BBP has paid dividends to shareholders.

PositionTTM20252024202320222021202020192018201720162015
BBP
Virtus LifeSci Biotech Products ETF		0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.18%0.00%1.29%
TXG
10x Genomics, Inc.		0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%

Frequently Asked Questions

TXG and BBP have a correlation of 0.37, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.

TXG has higher volatility (16.46%) compared to BBP (7.61%). In terms of maximum drawdown, TXG dropped -96.47% vs BBP's -44.32%.

TXG currently has the higher Sharpe Ratio (3.81 vs 1.91), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.

Portfolio Optimizer

Find the right allocation for TXG and BBP

Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.

Open Portfolio Optimizer